Evidence map›Paper›PMID 40775287›Full record

ArticleBMC infectious diseases2025

Characterization of private mutations in the spike protein of SARS-CoV-2 correlates with viral prevalence.

Shuo Wang, Ziyang Hao, Yuhan Ding, Heng Rong, Shuo Ning, Qiao Qiao, Xiaojuan Zhu, Tao Wu, Kangchen Zhao, Liguo Zhu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shuo Wang *School of Public Health, Nanjing Medical University, Nanjing, 210009, China.
Ziyang Hao *School of Public Health, Nanjing Medical University, Nanjing, 210009, China.
Yuhan DingNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Heng RongNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Shuo NingNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Qiao QiaoNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Xiaojuan ZhuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Tao WuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Kangchen ZhaoNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Liguo ZhuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Jingxin LiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Yiyue GeNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Medical Key Laboratory of Pathogenic Microbiology in Emerging Major Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China. geyiyue@jscdc.cn.
Lunbiao CuiSchool of Public Health, Nanjing Medical University, Nanjing, 210009, China. lbcui@jscdc.cn.

Funding

Jiangsu Provincial Key Research and Development Program BE2023601National Key Research and Development Program of China 2023YFC2605100, 2023YFC2605104Natural Science Foundation of Jiangsu Province BK20231374
6 · The paper itself

Abstract

backgroundSARS-CoV-2 has continued to spread globally since its outbreak. As the virus evolves, new variants affect the efficacy of current vaccines and treatments. Therefore, understanding and explaining the viral prevalence of SARS-CoV-2 is crucial for developing effective public health strategies.

methodsGenomic information from the SARS-CoV-2 network surveillance laboratories in Jiangsu Province in 2023 was collected. The impact of private mutations on binding affinity of the spike protein to Angiotensin Converting Enzyme 2 (ACE2) was evaluated by Bioinformatic analyses, pseudovirus infection assays and Bio-Layer Interferometry (BLI). The impact of private mutations on antibody escape capacity was evaluated through Pseudotyped Virus Neutralization Assay (PVNA).

resultsThe major circulating SARS-CoV-2 sublineages in Jiangsu Province in 2023 included BA.5.2*, XBB.1.5*, XBB.1.16*, XBB.1.22*, and XBB.1.9*. Key private mutations analyzed were E748V in XBB.1.5.24, H146K and I210T in XBB.1.22.1, H146K + I210T, and L455F in EG.5.1/EG.5.1.1. Bioinformatic analyses, pseudovirus infection assays, and BLI results showed that L455F significantly increased the spike protein's binding affinity to ACE2. PVNA results indicated that H146K and I210T enhance the antibody evasion ability of the XBB.1.22.1 spike protein, while L455F did so for EG.5.1/EG.5.1.1. However, E748V increased antibody neutralization sensitivity for XBB.1.5.24. E748V, I210T, and L455F became characteristic of their respective descent lineages GF.1, FY.3.1, and HK.3. The epidemic durations of FY.3.1 and HK.3 were longer than that of GF.1.

conclusionsContinuous monitoring and functional analysis of SARS-CoV-2 private mutations can be an effective approach for explaining patterns of viral prevalence. This has significant implications for the timely formulation of prevention and control measures.

Indexed as

COVID-19MutationSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralChinaHumansNeutralization TestsPrevalenceACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2EpidemicPrivate mutationsSARS-CoV-2Spike protein

Identifiers

PMID40775287
PMCPMC12333205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.